IN2015DN01328A - - Google Patents

Info

Publication number
IN2015DN01328A
IN2015DN01328A IN1328DEN2015A IN2015DN01328A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A IN 1328DEN2015 A IN1328DEN2015 A IN 1328DEN2015A IN 2015DN01328 A IN2015DN01328 A IN 2015DN01328A
Authority
IN
India
Prior art keywords
compounds
present
therapeutic
cancer
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek Rauniyar
Cynthia Shafer
Sharadha Subramanian
Huw Tanner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN01328A publication Critical patent/IN2015DN01328A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1328DEN2015 2012-09-19 2013-09-17 IN2015DN01328A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2015DN01328A true IN2015DN01328A (en:Method) 2015-07-03

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1328DEN2015 IN2015DN01328A (en:Method) 2012-09-19 2013-09-17

Country Status (13)

Country Link
US (1) US9546173B2 (en:Method)
EP (1) EP2897961B1 (en:Method)
JP (1) JP6186440B2 (en:Method)
KR (1) KR20150056550A (en:Method)
CN (1) CN104640865B (en:Method)
AU (1) AU2013318283A1 (en:Method)
BR (1) BR112015005982A2 (en:Method)
CA (1) CA2882410A1 (en:Method)
EA (1) EA201590600A1 (en:Method)
ES (1) ES2612885T3 (en:Method)
IN (1) IN2015DN01328A (en:Method)
MX (1) MX2015003535A (en:Method)
WO (1) WO2014047020A1 (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
WO2020011731A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
EP4007632A1 (en) * 2019-08-01 2022-06-08 Praetego, Inc. Inhibitors of advanced glycation end products
NZ787393A (en) 2019-12-10 2025-07-25 Hoffmann La Roche New methylquinazolinone derivatives
CR20220252A (es) * 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
CN115443274B (zh) 2020-04-30 2025-04-25 勤浩医药(苏州)有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251869A1 (en) * 2002-07-15 2004-02-02 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2005068468A2 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
KR100919343B1 (ko) 2005-01-10 2009-09-25 화이자 인코포레이티드 키네이스 억제제로서 피롤로피라졸
PL1966151T3 (pl) 2005-12-13 2012-02-29 Merck Sharp & Dohme Policykliczne pochodne indazoli jako inhibitory ERK
PE20090326A1 (es) 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
CN103298461A (zh) 2010-11-17 2013-09-11 霍夫曼-拉罗奇有限公司 治疗肿瘤的方法
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
ES2620612T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Also Published As

Publication number Publication date
BR112015005982A2 (pt) 2017-07-04
CA2882410A1 (en) 2014-03-27
CN104640865B (zh) 2018-05-11
US9546173B2 (en) 2017-01-17
AU2013318283A1 (en) 2015-03-05
CN104640865A (zh) 2015-05-20
EA201590600A1 (ru) 2015-07-30
ES2612885T3 (es) 2017-05-19
EP2897961B1 (en) 2016-10-26
EP2897961A1 (en) 2015-07-29
JP2015529248A (ja) 2015-10-05
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
WO2014047020A1 (en) 2014-03-27
JP6186440B2 (ja) 2017-08-23
MX2015003535A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TR201816379T4 (tr) DNA-PK inhibitörleri.
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
IN2014MN00986A (en:Method)
GT201500051A (es) Inhibidores de glucosilceramida sintasa
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
PH12015501385A1 (en) Autotaxin inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
IN2014MN02069A (en:Method)
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01328A (en:Method)
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
GEP201606566B (en) Isoxazolidine derivatives